Introduction
============

Sepsis is a systematic inflammatory response to infection and is the leading cause of death in intensive care units (ICUs) ([@b1-etm-0-0-4854],[@b2-etm-0-0-4854]). During sepsis, many types of danger-associated molecular patterns (DAMPs) that mediate inflammatory responses and organ failure are released into the blood ([@b3-etm-0-0-4854]--[@b5-etm-0-0-4854]). High mobility group box-1 (HMGB1) is a conserved non-histone DNA-binding protein that serves as a type of DAMP during many pathological processes, including sepsis and disseminated intravascular coagulation ([@b6-etm-0-0-4854]). It has previously been reported that high levels of HMGB1 are released into the blood as sepsis occurs, which subsequently mediate the inflammatory response. In a previous study by our group, it was demonstrated that HMGB1 enters the urine and mediates inflammation by transforming renal epithelial cells into inflammatory promoters during sepsis ([@b7-etm-0-0-4854]). However, the extent to which HMGB1 is released into the blood and enters the urine remains unclear.

As techniques improve, blood purification methods, including continuous renal replacement therapy (CRRT) and hemoperfusion (HP), are becoming more commonly used as treatment methods for sepsis ([@b8-etm-0-0-4854],[@b9-etm-0-0-4854]). Previous reports have suggested that the attenuation of several pro-inflammatory cytokines, such as interleukins and tumor necrosis factors, may be the primary underlying mechanism of blood purification as an effective treatment for sepsis ([@b10-etm-0-0-4854],[@b11-etm-0-0-4854]). However, other studies have reported no association between the attenuation of cytokines and the use of blood purification techniques during sepsis ([@b12-etm-0-0-4854],[@b13-etm-0-0-4854]). The exact mechanism of blood purification as a cure for sepsis remains unclear.

Previous studies have suggested that increased levels of serum HMGB1 may be associated with a poorer outcome in sepsis patients (SPs), and that clinical treatments that reduce HMGB1 may be effective for the treatment of sepsis ([@b14-etm-0-0-4854],[@b15-etm-0-0-4854]). HMGB1 is an important DAMP that amplifies the systemic inflammatory response, and blood purification is an effective cure for sepsis. Therefore, it is important to determine the extent to which serum and urine HMGB1 levels are elevated during sepsis, and the influence of blood purification treatments initiated immediately after sepsis diagnosis on serum and urine HMGB1 levels and sepsis prognosis. The present study aimed to answer these questions.

Materials and methods
=====================

### Study population

A total of 40 adult SPs with different sepsis severities, who were admitted to the ICU of Union Hospital (Fujian Medical University, Fuzhou, China) between January and December 2015, were enrolled in the present study. Informed consent was obtained from all patients or their legal representatives, and all study protocols were approved by the Ethics Committee of Fujian Medical University and followed regulations in accordance with the Declaration of Helsinki. Sepsis was defined according to the criteria of the American College of Chest Physicians/Society of Critical Care Medicine ([@b16-etm-0-0-4854]) and diagnosed as sepsis, severe sepsis or septic shock. The baseline characteristic data of the enrolled patients are presented in [Table I](#tI-etm-0-0-4854){ref-type="table"}. A total of 10 healthy volunteers (5 males and 5 females) who were absent of any disease were enrolled as a healthy control group (mean age, 57.25±13.78 years).

### Exclusion criteria

The exclusion criteria were as follows: Patients \<18 years old, patients with life-threatening water electrolyte/acid-base balance disorder within the first 24 h of the ICU stay, patients with end stage renal disease receiving any type of blood purification therapy, pregnancy, receipt of immunosuppressive therapy or human immunodeficiency virus infection, current participation in any other clinical trial and inability to be evaluated effectively during the study period.

### Clinical treatment

Immediately after a diagnosis of sepsis was confirmed, patients were randomly assigned to a control (no intervention) group without any apheresis treatment (sepsis group, n=10), a CRRT group (n=10), an HP group (n=10) and an HP+CRRT group (n=10). Blood purification treatments were initiated immediately after informed consent was obtained. A 12 Fr double lumen catheter was placed in the right femoral vein of each patient to establish vascular access. All blood purification treatments were conducted using a PrismaFlex system (Baxter International, Inc., Deerfield, IL, USA). Blood purification data are presented in [Table II](#tII-etm-0-0-4854){ref-type="table"}. With the exception of the blood purification treatments performed immediately following the diagnosis of sepsis, all other treatments were consistent among the groups. All patients were treated according to the Guidelines for Management of Severe Sepsis and Septic Shock (Surviving Sepsis Campaign International 2013) ([@b17-etm-0-0-4854]). The primary end point of the study was either patient survival at 30 days after enrollment or patient mortality during the 30-day period.

### ELISA tests

Serum and urine HMGB1 levels were measured using a Human HMGB1 ELISA kit (E-EL-H1554c, Elabscience Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer\'s protocol. Briefly, blood samples were obtained from peripheral vascular, blood and urine specimens (\~2 ml) were collected at the initiation of treatment and at 12 and 24 h thereafter. Blood specimens were maintained at room temperature for 2 h, and serum samples were collected prior to centrifugation. Serum and urine samples were centrifuged at 4°C in a swinging bucket rotor at 1,000 × g for 20 min, and the supernatant was collected and measured using the ELISA kit.

### Data collection

Following patient enrollment, the demographic data, sepsis type (sepsis, severe sepsis or septic shock), infection sites and biological data of patients were recorded. Acute Physiology and Chronic Health Evaluation (APACHE) II ([@b18-etm-0-0-4854]) scores were assigned at the initiation of treatment and 24 h later. All patients were observed for 30 days, and the mortality rate during this period was recorded. Information regarding patient medical history and preexisting conditions was obtained by examining the patients\' previous medical records.

### Statistical analyses

Statistical analyses were performed using GraphPad Prism version 6 (GraphPad Software Inc., La Jolla, CA, USA). Data are presented as the mean ± standard deviation. All variables were tested for normal distribution. Differences between groups were evaluated by analysis of variance and Tukey\'s multiple comparison tests were performed. Correlations between the serum and urine HMGB1 levels and APACHE II scores of the SP groups at the initiation of treatment (0 h) were calculated using Pearson\'s correlation analysis. Time-to-event data were compared using the Gehan-Breslow-Wilcoxon test for survival analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Serum and urine HMGB1 levels in different groups

The serum and urine HMGB1 levels of patients in different groups were measured using ELISA. The results indicated that upon diagnosis of sepsis, both the serum and urine HMGB1 levels were significantly increased in all SP groups when compared with the healthy control group (P\<0.05; [Fig. 1](#f1-etm-0-0-4854){ref-type="fig"}).

### Serum and urine HMGB1 levels in the sepsis group at different time points

To investigate the changes in serum and urine HMGB1 levels within the first 24 h of sepsis, serum and urine HMGB1 levels of patients in the sepsis group were measured at the time of sepsis diagnosis (0 h) and at 12 and 24 h thereafter. Serum HMGB1 levels increased gradually within the first 24 h of sepsis, and the serum HMGB1 level at 24 h after diagnosis was significantly increased compared with that at 0 h (P\<0.05; [Fig. 2A](#f2-etm-0-0-4854){ref-type="fig"}). By contrast, the urine HMGB1 level was significantly decreased at 12 and 24 h compared with that at 0 h (P\<0.05; [Fig. 2B](#f2-etm-0-0-4854){ref-type="fig"}).

### Correlations between the serum HMGB1 level, urine HMGB1 level and APACHE II score

Associations between serum and urine HMGB1 levels and APACHE II scores were analyzed using Pearson\'s correlation analysis. The results indicated a significant negative correlation between the serum HMGB1 level and urine HMGB1 level in the SP groups (r=−0.5103, P=0.026; [Fig. 3A](#f3-etm-0-0-4854){ref-type="fig"}). By contrast, the serum HMGB1 level and APACHE II score were significantly positively correlated in patients with sepsis (r=0.7284, P\<0.01; [Fig. 3B](#f3-etm-0-0-4854){ref-type="fig"}).

### Changes in the serum and urine HMGB1 levels in the blood purification groups

To investigate the effects of various treatments on serum and urine HMGB1 levels, serum and urine samples were collected from the different SP groups and measured using ELISA kits. The results indicated that serum HMGB1 was significantly increased in the sepsis group at 24 h compared with that of 0 and 12 h. Serum and urine HMGB1 levels were significantly reduced in the HP and HP+CRRT groups at 12 and 24 h following the initiation of treatment (P\<0.05; [Fig. 4](#f4-etm-0-0-4854){ref-type="fig"}). In the CRRT group, a significant reduction in serum HMGB1 was observed 24 h after the initiation of treatment (P\<0.05), while urine HMGB1 levels did not differ significantly between 0 and 24 h. The serum and urine HMGB1 levels of different groups were compared with those of the sepsis group at various time points. The results indicated that the serum and urine HMGB1 levels of the HP and HP+CRRT groups were significantly lower compared with that of the sepsis group at 12 and 24 h following the initiation of treatment (P\<0.05; [Fig. 4](#f4-etm-0-0-4854){ref-type="fig"}). By contrast, only the serum HMGB1 level was significantly decreased in the CRRT group compared with the sepsis group at 24 h (P\<0.05). In addition, urine HMGB1 levels in the CRRT and HP+CRRT groups 24 h after the initiation of treatment were significantly higher compared with those at 12 h (P\<0.05; [Fig. 4](#f4-etm-0-0-4854){ref-type="fig"}).

### Changes in APACHE II scores in the different groups

To determine the effects of different blood purification treatments on the short-term outcome of patients, the APACHE II scores of patients were measured. The APACHE II scores of the HP+CRRT group were significantly higher compared with all other SP groups at the initiation of treatment (P\<0.05; [Fig. 5](#f5-etm-0-0-4854){ref-type="fig"}). At 24 h post-initiation of treatment, the APACHE II scores of patients in the CRRT, HP and HP+CRRT groups were significantly decreased compared with those at 0 h (P\<0.05; [Fig. 5](#f5-etm-0-0-4854){ref-type="fig"}). Furthermore, at 24 h post-initiation of treatment, the APACHE II scores of the CRRT, HP and HP+CRRT groups were significantly lower compared with the sepsis group (P\<0.05; [Fig. 5](#f5-etm-0-0-4854){ref-type="fig"}).

### Survival outcome

After a 30-day follow-up period, the survival rates of the different SP groups were as follows: Sepsis group, 20%; CRRT group, 60%; HP group, 60%; and HP+CRRT group, 80% ([Fig. 6](#f6-etm-0-0-4854){ref-type="fig"}). Despite the higher survival rates of the CRRT and HP groups compared with that of the sepsis group, survival analysis demonstrated that the improvements were not statistically significant (P=0.0519 and P=0.0832, respectively). However, the results indicated that the 30-day survival rate of the HP+CRRT group was significantly higher compared with the sepsis group (P=0.0107), suggesting that combined treatment with HP+CRRT significantly improves the survival outcome of patients.

Discussion
==========

Sepsis is a major clinical syndrome associated with a high mortality rate in hospitalized patients ([@b19-etm-0-0-4854]). It has previously been demonstrated that extracellular HMGB1 serves as an important DAMP and activates the innate immune system ([@b20-etm-0-0-4854]--[@b22-etm-0-0-4854]). Animal studies have indicated that HMGB1 may be both actively and passively released into the blood during sepsis, and may act as an important proinflammatory cytokine that mediates the inflammatory response ([@b6-etm-0-0-4854],[@b7-etm-0-0-4854]). Pyroptosis and exocytosis of secretory lysosomes by activated immune cells are the primary processes that allow intercellular HMGB1 to reach extracellular spaces ([@b23-etm-0-0-4854],[@b24-etm-0-0-4854]). In the present study, it was observed that serum HMGB1 was significantly increased in SPs, and continued to rise during the development of sepsis. This is consistent with previous research ([@b25-etm-0-0-4854]) and suggests that serum HMGB1 serves an important role in the development of sepsis. A previous study also indicated that in specific pathological processes, including systemic lupus erythematosus ([@b26-etm-0-0-4854]), serum HMGB1 was able to infiltrate the urine; therefore, urine HMGB1 levels may be closely related to the severity of such diseases. The results of the present study indicated that urine HMGB1 levels were also significantly increased in SPs. HMGB1 may be excreted in the urine ([@b26-etm-0-0-4854],[@b27-etm-0-0-4854]), which suggests that urine is an important route for HMGB1 excretion during sepsis. Furthermore, results of the present study indicated that urine HMGB1 levels were significantly decreased at 12 and 24 h following confirmed sepsis diagnosis, suggesting that extracellular excretion of HMGB1 via the urine decreases as sepsis progresses.

To further investigate the association between serum HMGB1 levels and the severity of sepsis, a correlation analysis of serum HMGB1 levels and APACHE II scores was performed. The results suggested that patients with more severe sepsis had higher levels of serum HMGB1. Furthermore, results of the correlation analysis indicated that the urine HMGB1 level was negatively correlated with the serum HMGB1 level. These results suggest that as the clearance of HMGB1 decreases, the accumulation of serum HMGB1 is correlated with the aggravation of sepsis.

It is important to identify an effective method that attenuates serum HMGB1 levels and enhances the clearance of HMGB1 during the early stages of sepsis. Previous studies have indicated that blood purification techniques are able to directly and indirectly reduce the levels of proinflammatory cytokines in the blood ([@b28-etm-0-0-4854]--[@b30-etm-0-0-4854]). Similar to cytokines, the molecular weight of HMGB1 is relatively low (\~30 kDa) ([@b31-etm-0-0-4854]), and thus serum HMGB1 may also be effectively cleared by specific blood purification techniques initiated upon diagnosis of sepsis. In the present study, three different blood purification techniques were used (CRRT, HP and HP+CRRT) and the serum and urine HMGB1 levels were measured at different time points. Despite enhanced clearance of serum HMGB1 by the blood purification techniques, the results indicated that HP and HP+CRRT were more effective than CRRT. As activated carbon can absorb hydrophobic proteins, the HP technique may directly clear serum HMGB1; further research is required to confirm this. However, as the cut-off molecular weight of the hemofilter used in the current study was \~15--20 kDa, as reported previously ([@b32-etm-0-0-4854]), it was concluded that HMGB1 may not be directly cleared by CRRT. It was therefore hypothesized that CRRT may enhance the clearance of serum HMGB1 by increasing the excretion of HMGB1 via the urine. The urine and serum HMGB1 levels were measured at different time points and the results suggested that, although all urine and serum HMGB1 levels were markedly attenuated 12 h after the initiation of treatment, urine HMGB1 levels in the CRRT and HP+CRRT groups were significantly increased at 24 compared with 12 h. CRRT is able to continuously stabilize the internal environment and eliminate low molecular weight metabolic waste products of patients, including creatinine and urea nitrogen ([@b33-etm-0-0-4854],[@b34-etm-0-0-4854]), which suggests that CRRT treatment enhances the excretion of HMGB1 via the urine.

The effects of different blood purification treatments on the prognosis of SPs were investigated. The results indicated that although early HP+CRRT was the most effective method for reducing the APACHE II scores of patients, all three treatments effectively attenuated the APACHE II scores. These findings paralleled the reduction in serum HMGB1 levels in each group. As APACHE II score has been correlated with the short-term prognosis of SPs ([@b35-etm-0-0-4854]--[@b37-etm-0-0-4854]), the present data indicated that all of the investigated treatments were able to improve the short-term prognosis of SPs. Furthermore, results of the 30-day survival analysis indicated that, although all blood purification treatments were able to increase the survival rate of SPs at early-stage sepsis, only the HP+CRRT treatment significantly improved patients\' 30-day survival rate.

The present study was a randomized single-center clinical trial with a limited sample size; as such, multi-center studies are now warranted to verify the present findings. Future studies are also required to determine the exact mechanism underlying HMGB1 excretion, and the mechanisms by which blood purification techniques affect serum/urine HMGB1 levels and the prognosis of sepsis.

In conclusion, the present study demonstrated that serum and urine HMGB1 levels were significantly increased during sepsis, and the greatest increases in serum HMGB1 levels were positively correlated with the severity of sepsis and reduced excretion of HMGB1 in the urine. Blood purification treatments, particularly HP+CRRT, initiated immediately upon diagnosis of sepsis, effectively attenuated serum HMGB1 levels, promoted the excretion of HMGB1 via the urine and improved the prognosis of sepsis. Sepsis is a complicated clinical syndrome that lacks specific treatment methods, and the removal of common proinflammatory cytokines does not fully explain the effects of blood purification on sepsis ([@b38-etm-0-0-4854]). The results of the present study may provide a novel perspective regarding the mechanism of blood purification in sepsis, and may aid to develop a novel treatment strategy for sepsis.
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![Changes in serum and urine HMGB1 levels over 24 h. (A) Serum and (B) urine levels of HMGB1 in the sepsis (no apheresis intervention) group at different time points. Data are presented as the mean ± standard deviation. ^\#^P\<0.05 vs. 0-h value. HMGB1, high mobility group box protein 1.](etm-14-04-3029-g01){#f2-etm-0-0-4854}

![Association of serum HMGB1 level with urine HMGB1 level and APACHE II score. Correlations were identified between (A) urine and serum HMGB1 levels, and (B) APACHE II score and serum HMGB1 level in the sepsis (no apheresis intervention) group. HMGB1, high mobility group box protein 1; APACHE II, Acute Physiology and Chronic Health Evaluation II.](etm-14-04-3029-g02){#f3-etm-0-0-4854}

![Changes in serum and urine HMGB1 levels in the different patient groups over 24 h. (A) Serum and (B) urine levels of HMGB1 were measured by ELISA at different time points after the initiation of treatments. Data are presented as the mean ± standard deviation. ^\#^P\<0.05 vs. 0-h value; \*P\<0.05 vs. sepsis group; ^\^^P\<0.05 vs. 12-h value. HMGB1, high mobility group box protein 1; CRRT, continuous renal replacement treatment; HP, hemoperfusion.](etm-14-04-3029-g03){#f4-etm-0-0-4854}

![APACHE II scores of patients in different groups upon initiation of treatment (0 h) and 24 h thereafter. Data are presented as the mean ± standard deviation. ^&^P\<0.05 vs. all other groups at 0 h; ^\#^P\<0.05 vs. 0-h value; \*P\<0.05 vs. sepsis group at 24 h. APACHE II, Acute Physiology and Chronic Health Evaluation II; CRRT, continuous renal replacement treatment; HP, hemoperfusion.](etm-14-04-3029-g04){#f5-etm-0-0-4854}

![Survival curves demonstrating the 30-day survival rates of patients in different groups. CRRT, continuous renal replacement treatment; HP, hemoperfusion.](etm-14-04-3029-g05){#f6-etm-0-0-4854}

###### 

Baseline characteristics of patients prior to the initiation of treatment.

                               Group                                                       
  ---------------------------- ------------- --------------- ------------- --------------- ------
  Demographic data                                                                         
    Age, years                 56.60±14.16   61.50±13.16     59.10±20.34   57.70±15.62     0.91
    Male, %                    4 (40)        6 (60)          6 (60)        5 (50)          N/A
    MAP, mmHg                  51.85±9.84    56.45±16.27     54.06±14.00   55.77±12.57     0.87
  Type of infection, n (%)                                                                 
    Pulmonary                  4 (40)        6 (60)          4 (40)        5 (50)          N/A
    Abdominal                  1 (10)        3 (30)          2 (20)        1 (10)          N/A
    Skin and soft tissue       2 (20)        0 (0)           2 (20)        3 (30)          N/A
    Other                      3 (30)        1 (1)           2 (20)        1 (10)          N/A
  Biological data                                                                          
    WBC, ×10^3^/mm^3^          17.07±5.06    22.32±9.23      24.03±8.56    19.59±6.23      0.14
    HB, g/l                    83.53±5.09      90.32±10.74   83.72±6.40      84.09±10.06   0.22
    PCT, ng/ml                 20.52±5.10    16.98±7.83      23.20±7.76    18.05±8.03      0.24
    ALB, g/l                   28.93±6.49    28.05±7.32      27.28±7.77    26.72±5.31      0.90
  Type of sepsis, n (%)                                                                    
    Sepsis                     2 (20)        2 (20)          3 (30)        1 (10)          N/A
    Severe sepsis              7 (70)        6 (60)          6 (60)        5 (50)          N/A
    Septic shock               1 (10)        2 (20)          1 (10)        4 (40)          N/A
  Pathogens, n (%)                                                                         
    MRSA                       3 (30)        4 (40)          3 (30)        4 (40)          N/A
    *Pseudomonas aeruginosa*   2 (20)        4 (40)          3 (30)        3 (30)          N/A
    *Acinetobacter baumanii*   5 (50)        3 (30)          4 (40)        4 (40)          N/A
    Other bacteria             2 (20)        1 (10)          0 (0)         2 (20)          N/A
  Organ Dysfunction, n (%)                                                                 
    None                       2 (20)        2 (20)          3 (30)        1 (10)          N/A
    Lung                       8 (80)        7 (70)          7 (70)        9 (90)          N/A
    Kidney                     1 (10)        2 (20)          1 (10)        3 (30)          N/A
    Gastrointestinal           0 (0)         1 (10)          0 (0)         1 (10)          N/A
    Liver                      0 (0)         0 (0)           1 (10)        1 (10)          N/A

Demographic and biological data are presented as the mean ± standard deviation. CRRT, continuous renal replacement treatment; HP, hemoperfusion; N/A, not applicable; MAP, mean arterial pressure; WBC, white blood cells; HB, hemoglobin; PCT, procalcitonin; ALB, human serum albumin; MRSA, Methicillin-resistant *Staphylococcus aureus*.

###### 

Blood purification therapy data for the different groups.

  Group    Filter set     Time, h         BF, ml/min   CTD, ml/kg/h   Pre/post   Heparin, IU/kg/h
  -------- -------------- --------------- ------------ -------------- ---------- ------------------
  Sepsis   N/A            N/A             N/A          N/A            N/A        N/A
  CRRT     M100 Set       24              180          35             2:1        5
  HP       Adsorba 300    2.5             180          N/A            N/A        5
  HP+      M100 Set       HP+CRRT         180          35             2:1        5
  CRRT     +Adsorba 300   2.5+CRRT 21.5                                          

CRRT, continuous renal replacement treatment; HP, hemoperfusion; N/A, not applicable; BF, blood flow; CTD, CRRT treatment dose; Pre, pre-substitution; Post, post-substitution.
